Is COAG or PNTG more profitable?

PNTG runs the higher net margin — COAG at 0.00% versus PNTG at 2.93%.

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) vs The Pennant Group, Inc. (PNTG)

A side-by-side comparison of Hemab Therapeutics Holdings, Inc. Common Stock and The Pennant Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

$1.36B

$29.21HealthcareDelayed quote: Oct 6, 2026, 12:05 PM EDT

PNTG

The Pennant Group, Inc.

$1.42B

$40.76HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT

Total return — COAG vs PNTG

growth of $100 · dividends reinvested · last 1y

COAG -10.0% (-10.0%/yr)PNTG +28.8% (+28.8%/yr)PNTG compounded faster over this window

COAG PNTG

COAG vs PNTG: by the numbers

•PNTG is the larger company ($1.42B vs $1.36B market cap).
•PNTG is profitable (2.93% net margin) while COAG runs a net loss (0.00%).

Metrics side by side

Valuation

Metric	COAG	PNTG
P/E ratio	N/A	45.29
Forward P/E	N/A	29.20
PEG ratio	N/A	4.50
P/S ratio	N/A	1.29
P/B ratio	3.00	3.94
EV / EBITDA	N/A	25.72
FCF yield	N/A	1.83%

Profitability

Metric	COAG	PNTG
Gross margin	0.00%	14.79%
Operating margin	0.00%	5.77%
Net margin	0.00%	2.93%
ROE	N/A	9.00%
ROIC	-38.09%	5.22%

Growth (annualized)

Metric	COAG	PNTG
Revenue CAGR (5Y)	N/A	21.14%
EPS CAGR (5Y)	N/A	8.96%
Total return CAGR (5Y)	N/A	8.88%

Frequently asked

Is COAG or PNTG more profitable?: PNTG runs the higher net margin — COAG at 0.00% versus PNTG at 2.93%.

Go deeper

Full COAG analysis Full PNTG analysis Interactive comparison tool

Dig into the metrics

Pennant P/E ratio Hemab Therapeutics Holdings, Inc. Common Stock ROE Pennant ROE Hemab Therapeutics Holdings, Inc. Common Stock operating margin Pennant operating margin Hemab Therapeutics Holdings, Inc. Common Stock revenue growth Pennant revenue growth Hemab Therapeutics Holdings, Inc. Common Stock free cash flow Pennant free cash flow

Hemab Therapeutics Holdings, Inc. Common Stock & Pennant appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.